Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in pediatric colchicine-resistant or colchicine-intolerant familial Mediterranean fever
2015-003522-13Phase 2
- Sponsor
- Novartis
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canakinumab in Familial Mediterranean fever (FMF), sponsored by Novartis. Primary endpoint: At least 50% reduction in FMF attack frequency.
02
Drugs
canakinumab
03
Conditions
Familial Mediterranean fever (FMF)
Beyond the preview
Go deeper on 2015-003522-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003522-13.